Hormonal Treatments of Endocrine-Dependent Tumors: Preclinical Aspects

  • P. Magni
  • M. Motta
Conference paper


Breast and prostate carcinomas are the most frequently diagnosed diseases in the group of the so-called endocrine-dependent tumors. These diseases are given this name because their development and maintenance, and in several instances their progression, are sustained by the presence of gonadal hormones in the bloodstream, namely estrogens in females and androgens, particularly testosterone, the main testicular androgen, in males.


Breast Cancer Prostate Cancer Androgen Receptor Aromatase Inhibitor GnRH Agonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Auclerc G., Antoine E.C., Cajfinger F., Brunet-Pommeyrol A., Agazia C, Khayat D. (2000). Management of advanced prostate cancer. Oncologist, 5, 36–44.PubMedCrossRefGoogle Scholar
  2. Bologna M., et al. (1992). Anti-androgens and 5alpha-reductase inhibition of the proliferation rate in PC3 and DU145 human prostatic cancer cell line. Curr Ther Res, 51,799–813.Google Scholar
  3. Bologna M., et al. (1995). Finasteride dose-dependently reduces the proliferation rate of the LnCAP human prostatic cancer cell line in vitro. Urology, 45, 282–290.PubMedCrossRefGoogle Scholar
  4. Bonneterre J., et al. (2000). Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol, 18, 3748–3757.PubMedGoogle Scholar
  5. Buzdar A. and Hortobagyi G. (1998). Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol, 16, 348–353.PubMedGoogle Scholar
  6. Coltman C.A., et al. (1999). Prostate cancer prevention trial (PCPT) update. Eur Urol, 35, 544–547.PubMedCrossRefGoogle Scholar
  7. Cook T., Sheridan W.P. (2000). Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist, 5, 162–168.PubMedCrossRefGoogle Scholar
  8. Cummings S., et al. (1999). The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomised trial. Multiple Outcomes of Raloxifene Evaluation. JAMA, 281, 2189–2197.PubMedCrossRefGoogle Scholar
  9. Denis L. and Griffiths K. (2000). Endocrine treatment in prostate cancer. Semin Surg Oncol, 18, 52–74.PubMedCrossRefGoogle Scholar
  10. Dowsett M., et al. (1995). In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in post-menopausal patients with breast cancer. Clin Cancer Res, 1, 1511–1515.PubMedGoogle Scholar
  11. Filardo E., et al. (2000). Estrogen-induced activation of Erk-i and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via fraws-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol, 14, 1649–1660.PubMedCrossRefGoogle Scholar
  12. Fisher B., et al. (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-i Study. J Natl Cancer Inst, 90, 1371–1388.PubMedCrossRefGoogle Scholar
  13. Fisher B., et al. (1999). Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet, 353, 1993–2000.PubMedCrossRefGoogle Scholar
  14. Fradet Y., et al. (1999). Dietary fat and prostate cancer progression and survival. Eur Urol, 35, 388–391.PubMedCrossRefGoogle Scholar
  15. Gale K., et al. (1994). Hormonal treatment for metastatic breast cancer: an Eastern Cooperative Oncology Group Phase III trial comparing aminogluthetimide to tamoxifen. Cancer, 73,354–361.PubMedCrossRefGoogle Scholar
  16. Gormley G. (1996). 5alpha-reductase inhibitors in prostate cancer. Endocrine-Related Cancer, 3, 57–63.CrossRefGoogle Scholar
  17. Ingle J., et al. (1999). Evaluation of tamoxifen plus letrozole with assessment of pharma-cokinetic interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res, 5, 1642–1649.PubMedGoogle Scholar
  18. MacNeill R, et al. (1992). The influence of aminoglutethimide and its analogue rogle- timide on peripheral aromatisation in breast cancer. Br I Cancer, 66, 692–697.CrossRefGoogle Scholar
  19. Mor G., et al. (1998). Macrophages, estrogen and the microenvironment of breast cancer. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity. J Steroid Biochem Mole Biol, 67, 403–411.CrossRefGoogle Scholar
  20. Mouridsen H., et al. (2001). Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol, 19, 2596–2606.PubMedGoogle Scholar
  21. Nabholtz J., et al. (2000). Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol, 18, 3758–3767.PubMedGoogle Scholar
  22. Paech K. et al. (1997). Differential ligand activation of estrogen receptors ERalpha and ERbeta at APi sites. Science, 277, 1508–1510.PubMedCrossRefGoogle Scholar
  23. Petterson K. and Gustafsson J. (2001). Role of estrogen receptor beta in estrogen action. Annu Rev Physiol, 63, 165–192.CrossRefGoogle Scholar
  24. Porter W., et al. (1997). Functional synergy between the transcription factor Spi and the estrogen receptor. Mol Endocrinol, 11, 1569–1580.PubMedCrossRefGoogle Scholar
  25. Powles T., et al. (1998). Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet, 352, 98–101.PubMedGoogle Scholar
  26. Sanford E.J., et al. (1977). The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma. J Urol, 118, 1019–1021.PubMedGoogle Scholar
  27. Santen R. and Harvey H. (1999). Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer, 6, 75–92.PubMedCrossRefGoogle Scholar
  28. Santen R., et al. (1990). Endocrine treatment of breast cancer in women. Endocr Rev, 11, 221–265.PubMedCrossRefGoogle Scholar
  29. Siiteri P.K. (1987). Adipose tissue as a source of hormones. Am J Clin Nutr, 45, 277–82.PubMedGoogle Scholar
  30. Small E. and Srinivas S. (1995). The anti-androgen withdrawal syndrome: experience in a large cohort of unselected patients with advanced prostate cancer. Cancer, 76, 1428–1434.PubMedCrossRefGoogle Scholar
  31. Smith I., et al. (1982). Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res, 42 (8 Suppl), 3430S–3433S.PubMedGoogle Scholar
  32. Takayama K., et al. (1997). Transcriptional regulation of CYP19 gene (aromatase) expression in adipose stromal cells in primary culture. J Clin Endocrinol Metab, 82, 600–606.PubMedCrossRefGoogle Scholar
  33. Taplin M., et al. (1995). Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med, 332, 1393–1398.PubMedCrossRefGoogle Scholar
  34. Veronesi U., et al. (1998). Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet, 352, 93–97.PubMedGoogle Scholar
  35. Zhang Y., et al. (1997). Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med, 336, 661–617.CrossRefGoogle Scholar
  36. Zumoff B. (1998). Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical, and clinical investigative studies to a resolution of the controversy. Proc Soc Exp Biol Med, 217, 30–37.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2003

Authors and Affiliations

  • P. Magni
  • M. Motta

There are no affiliations available

Personalised recommendations